Zurück
HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
HCID 2471Erstellt: 26. Oktober 2026

Bumetanid

3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid · bumex · Lixil · pf159 · DONALD · burine · pf1593 · Bufenox

https://huagongshe.com/de/chemical/2471

Molekülstruktur von Bumetanid

Identifikatoren & physikalische Daten

CAS No.28395-03-1
SummenformelC17H20N2O5S
Durchschnittliche Molmasse364,4 g/mol
Monoisotopische Masse364,10929292 g/mol
SMILESCCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1
InChIKeyMAEIEVLCKWDQJH-UHFFFAOYSA-N
PubChem CID2471
ChEMBLCHEMBL1072
ChEBICHEBI:3213
EC No.249-004-6
DTXSIDDTXSID5022699
Lokaler NameBumetanid

Chemische & physikalische Eigenschaften

XLogP2,8
Polarare Oberfläche (TPSA)127
H-Brücken-Donoren3
H-Brücken-Akzeptoren7
Frei drehbare Bindungen8
Schwere Atome25
Formalladung0
Komplexität528
LogP (Verteilungskoeffizient)2.6
Löslichkeit>20 mg/mL (in base)2.57e-02 g/L>54.7 [ug/mL] (The mean of the results at pH 7.4)Practically insoluble in water, soluble in acetone and in alcohol, slightly soluble in methylene chloride. It dissolves in dilute solutions of alkali hydroxides.Soluble in ethanol (10 mg/ml), DMSO (25 mg/ml), acetone, benzene, methanol, propylene glycol, and water (<1 mg/ml).
Schmelzpunkt230-231230 - 231 °C230-2310C
Physical DescriptionSolid
Dissociation Constants3.833.6
Collision Cross Section185.1 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]195.27 Ų [M+K]+ [CCS Type: TW168.69 Ų [M+H-H2O]+ [CCS Type: TW193.48 Ų [M+Na]+ [CCS Type: TW
Siedepunkt571.2±60.0 °C(Predicted)
Dichte1.2812 (rough estimate)
Brechungsindex1.6510 (estimate)
Lagerbedingungen2-8°C
AggregatzustandSolid
pKa (Säurekonstante)pK1 3.6, pK2 7.7(at 25℃)
FarbeWhite to Light Yellow
Hauptanwendungenpharmaceutical (small molecule)
InChIInChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)
InChIKeyMAEIEVLCKWDQJH-UHFFFAOYSA-N
SMILESC(O)(=O)C1=CC(NCCCC)=C(OC2=CC=CC=C2)C(S(N)(=O)=O)=C1
CAS Datenbank28395-03-1(CAS DataBase Reference)
EPA chemische InformationenBenzoic acid, 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy- (28395-03-1)

Sicherheit & Vorschriften

GHS-EinstufungWarningH315 (75%): Causes skin irritation [Warning Skin corrosion/irritation]H319 (75%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]H335 (75%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposureRespiratory tract irritation]H361d (25%): Suspected of damaging the unborn child [Warning Reproductive toxicity]P203, P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 4 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
Weitere SicherheitsinformationenIMAP assessments - Benzoic acid, 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy-: Human health tier I assessmentIMAP assessments - Benzoic acid, 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy-: Environment tier I assessment
Hazard Classes and CategoriesSkin Irrit. 2 (75%)Eye Irrit. 2A (75%)STOT SE 3 (75%)Repr. 2 (25%)
Unerwünschte WirkungenThe most common adverse events associated with bumetanide include hyperuricemia (characteristic of all loop diuretics), hypochloremia, hypokalemia, azotemia, and hyponatremia. Other less common adverse effects include hyperglycemia, increased serum creatinine, muscle weakness, and hearing impairment. Rare but significant or potentially life-threatening adverse reactions include hypotension (including orthostatic hypotension), encephalopathy (in instances of pre-existing hepatic disease), and renal failure. All loop diuretics exhibit potent diuresis capabilities, and excessive amounts can lead to significant diuresis with fluid and electrolyte lossclose medical supervision is necessary when administering these agents.
ToxizitätsübersichtExtensive or too frequent dosage can lead to acute volume and electrolyte depletion, low circulatory volume with a possibility of vascular thrombosis, and embolism. Symptoms such as weakness, mental confusion, anorexia, lethargy, vomiting, and cramps may occur because of electrolyte depletion. Treatment is with the adequate replacement of fluids and electrolytes, such as adding potassium supplements or potassium-sparing diuretics in case of potassium depletion. Asymptomatic hyperuricemia and slight reversible elevations of BUN and creatinine may also occur, particularly associated with dehydration or patients with renal insufficiency. Bumetanide has shown an increase in urinary calcium with resultant hypocalcemia. Similarly, hypomagnesemia should be measured periodically.
Drug Induced Liver InjuryDrug Induced Liver Injury Rank (DILIrank 2.0)BumetanideAmbiguous-DILI-concern3Warnings & precautionsDOI:10.1016/j.drudis.2016.02.015
Effects During Pregnancy and Lactation◉ Summary of Use during LactationIt is unknown if bumetanide is excreted into breastmilk. It should be avoided while breastfeeding a newborn because it may decrease milk flow or completely suppress lactation. Low doses in mothers whose lactation is well established are unlikely to suppress lactation.◉ Effects in Breastfed InfantsRelevant published information was not found as of the revision date.◉ Effects on Lactation and BreastmilkRelevant published information on bumetanide was not found as of the revision date. Intense diuresis, fluid restriction and breast binding have been used to suppress lactation immediately postpartum. The added contribution of the diuretic to the other measures, which are effective in suppressing lactation, has not been studied. No data exist on the effects of loop diuretics on established, ongoing lactation.
Wassergefährdungsklasse (WGK)3
Zollcode2935904000
RTECS-Nr.DG4910000
ToxizitätLD50 i.v. in mice: 330 mg/kg (Oestergaard)
Lagerklasse11 - Combustible Solids

Anwendungen & Verwendung

Verwenden

Bumetanide is a diuretic.